Combination chemotherapy with capecitabine (X) and cisplatin (P) as first Line treatment in advanced gastric cancer: Experience of 223 patients with prognostic factor analysis

Japanese Journal of Clinical Oncology

Volumn 37, Issue 1, 2007, Pages 30-37

  Lee, Sung Sook ^a   Lee, Jae Lyun ^a   Ryu, Min Hee ^a   Chang, Heung Moon ^a   Kim, Tae Won ^a   Kang, Hye Jin ^a   Kim, Woo Kun ^a   Lee, Jung Shin ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Capecitabine; Chemotherapy; Cisplatin; Prognostic factor

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; FUROSEMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FACTORIAL ANALYSIS; FEMALE; FOLLOW UP; GASTRECTOMY; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; STOMACH CANCER; STOMACH CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34547132086     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl134     Document Type: Article

References (23)

1. Alberts SR. Cervantes A, van de Velde CJH. Gastric cancer: Epidemiology, pathology and treatment. Ann Oncol 2003;14(Suppl 2): I31-6.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
5. Kim NK, Park YS, Heo DS, Sub C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil Alone in the treatmemt of advanced gastric cancer. Cancer 1993;71:3813-8.
6. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
7. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori T, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
9. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;34:291-7.
10. Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, et al. Expression of thymidine phosphorylase in human gastric carcinoma, Jpn J Cancer Res 1996;87:288-95.
11. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996;73:884-8.
12. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, et al. A Phase II trial of capecitabine in previously untreated patients with advanced and/ or metastatic gastric cancer. Ann Oncol 2004:15:1344-7.
13. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T. Clinical Study Group of Capecitabine. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003; 64:232-6.
14. Kondo K, Chin K, Sakamoto J, Kojima H, Terashima M, Yamamura Y, et al. A multicenter phase II trial using 4-week cycles of capecitabine in advanced/metastatic gastric cancer (AGC). Proc Am Soc Clin Oncol 2003;22:321 (abstr. 1289).
15. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2003;13:1893-8.
16. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 2005;92:246-51.
17. Kang YK, Kang WK, Shin DB, Chen J, Xong J, Wang J, et al. Similar safety results of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/ cisplatin (FP) from a phase III trial in patients (pts) with previously untreated advanced gastric cancer (AGC). European Cancer Conference 13, 2005 (abstr. 721).
18. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-403.
19. Polee MB, Hop WCJ, Kok TC, Eskens FA, van der Burg ME, Splinter TA, et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 2003;89:2045-50.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatmemt in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
21. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115-20.
22. Pivot X, Chamorey E, Guardiola E, Magne N, Thyss A, Otto J, et al. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 2003;14:1578-86.
23. Hitt R, Jimeno A, Rodriguez-Pinilla M, Rodriguez-Peralto JL, Millan JM, Lopez-Martin A, et al. Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer 2004; 91:2005-11.